These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34030872)

  • 1. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
    Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
    Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.
    Fung J; Wong T; Chok K; Chan A; Cheung TT; Dai JW; Sin SL; Ma KW; Ng K; Ng KT; Seto WK; Lai CL; Yuen MF; Lo CM
    Hepatology; 2017 Oct; 66(4):1036-1044. PubMed ID: 28370215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral treatment for hepatitis B virus recurrence following liver transplantation.
    Lee S; Kwon CH; Moon HH; Kim TS; Roh Y; Song S; Shin M; Kim JM; Park JB; Kim SJ; Joh JW; Lee SK
    Clin Transplant; 2013; 27(5):E597-604. PubMed ID: 24093615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
    Urabe A; Imamura M; Tsuge M; Kan H; Fujino H; Fukuhara T; Masaki K; Kobayashi T; Ono A; Nakahara T; Kawaoka T; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Maki N; Ohdan H; Chayama K
    J Gastroenterol; 2017 Mar; 52(3):366-375. PubMed ID: 27422771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B.
    Perrillo R; Buti M; Durand F; Charlton M; Gadano A; Cantisani G; Loong CC; Brown K; Hu W; Lopez-Talavera JC; Llamoso C
    Liver Transpl; 2013 Aug; 19(8):887-95. PubMed ID: 23788462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
    Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis in liver transplantation recipients after hepatitis B virus recurrence.
    Sun LY; Zhu ZJ; Qu W; Sun XY; Rao W; Liu Y
    Hepatogastroenterology; 2014 Oct; 61(135):2047-51. PubMed ID: 25713909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
    Huang G; Yang Y; Shen F; Pan ZY; Fu SY; Lau WY; Zhou WP; Wu MC
    Ann Surg Oncol; 2013 May; 20(5):1482-90. PubMed ID: 23247982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of Preoperative Antiviral Treatment of Patients with HCC Negative for HBV-DNA.
    Liu XF; Zhang T; Tang K; Sui LL; Xu G; Liu Q
    Anticancer Res; 2017 Aug; 37(8):4701-4706. PubMed ID: 28739774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
    Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
    Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.